Edition:
United Kingdom

Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

646.90INR
11:28am BST
Change (% chg)

Rs-1.45 (-0.22%)
Prev Close
Rs648.35
Open
Rs650.05
Day's High
Rs655.50
Day's Low
Rs643.70
Volume
2,915,387
Avg. Vol
2,641,061
52-wk High
Rs663.40
52-wk Low
Rs507.20

Chart for

About

Cipla Limited is a holding company. The Company is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered... (more)

Overall

Beta: 0.47
Market Cap(Mil.): Rs471,067.19
Shares Outstanding(Mil.): 804.69
Dividend: 2.00
Yield (%): 0.34

Financials

  CIPL.NS Industry Sector
P/E (TTM): 43.76 30.93 32.76
EPS (TTM): 13.38 -- --
ROI: -- 15.07 14.61
ROE: -- 16.59 16.33

UPDATE 1-India's Sun Pharma Q1 profit beats estimates as U.S. sales climb

* Stock top gainer on NSE index (Adds details on U.S. and India sales, share movement)

14 Aug 2018

UPDATE 1-India's Cipla Q1 profit trumps estimates on strong domestic growth

* India revenue up 22 pct (Adds detail, share movement, appointment of global COO)

08 Aug 2018

India's Cipla Q1 profit trumps estimates

Aug 8 Cipla Ltd, India's third-largest drugmaker by market capitalisation, posted on Wednesday a more than 10 percent rise in its first-quarter profit, well above analysts' expectations.

08 Aug 2018

Indian shares fall as oil companies slip; Vedanta hits over 10-month low

May 23 Indian shares fell on Wednesday pulled down by oil companies, while mining and energy conglomerate Vedanta Ltd hit an over 10-month low as protests against its copper plant in south India turned violent.

23 May 2018

UPDATE 1-India's Cipla posts Q4 profit, misses estimates

May 22 Cipla Ltd, India's second-biggest drugmaker by market capitalization, posted a fourth-quarter profit on Tuesday, but missed street estimates.

22 May 2018

India's Cipla posts Q4 profit

May 22 Cipla Ltd, India's second-biggest drugmaker by market capitalization, posted a fourth-quarter profit on Tuesday, but missed analysts' estimates.

22 May 2018

BRIEF-Cipla Partners With Mannkind For Marketing, Distribution Of Afrezza In India

* PARTNERS WITH MANNKIND FOR EXCLUSIVE MARKETING, DISTRIBUTION OF AFREZZA IN INDIA

09 May 2018

BRIEF-Mannkind And Cipla Enter An Exclusive Marketing And Distribution Agreement For Afrezza® In India

* MANNKIND AND CIPLA ENTER AN EXCLUSIVE MARKETING AND DISTRIBUTION AGREEMENT FOR AFREZZA® IN INDIA

09 May 2018

BRIEF-India's Cipla Gets Final Nod For Generic Vazculep, Others

* GETS FINAL NOD FOR GENERIC VAZCULEP, GENERIC PHENYLEPHRINE HYDROCHLORIDE INJECTION USP, 10 MG/ML SINGLE-DOSE VIAL, GENERIC AROMASIN

02 May 2018

BRIEF-Cipla's JV Saba Investment Completes Disinvestment Of Stake Held In Al Jabal For Drugs And Medical Appliances

* CO'S JV SABA INVESTMENT COMPLETED DISINVESTMENT OF 99 PERCENT STAKE HELD IN AL JABAL FOR DRUGS AND MEDICAL APPLIANCES CO Source text: http://bit.ly/2GsCYiw Further company coverage:

26 Mar 2018

Earnings vs. Estimates